Additively manufactured subperiosteal jaw implant for jaw rehabilitation: is there evidence to support its recommendation?

Abstract

In 2017, Mommaerts described a new concept for the rehabilitation of atrophic jaws using customized additively manufactured subperiosteal jaw implants (AMSJI®). AMSJI® incorporated elements of computer-aided design and manufacturing (CAD/CAM) and new materials into traditional subperiosteal implants, developed over 80 years ago. As it is a rehabilitation that does not require bone reconstruction, it has been presented as a faster rehabilitation solution with less morbidity. However, it is important to clarify that AMSJI® is not exempt from complications, which may involve the soft tissues and/or hard tissues adjacent to the implant. Given that the data available on the use of customized subperiosteal implants manufactured by additive manufacturing is scarce, it is not yet possible to establish clinical recommendations based on robust scientific evidence. It is therefore the consensus of the authors of this study that, despite its possible promising potential, AMSJI® should not be the surgical procedure of choice for rehabilitating atrophic jaws and its indication should be restricted to cases in which other available therapeutic options are not viable.